EP Patent

EP3368012A1 — Lisinopril formulations

Assigned to Silvergate Pharmaceuticals Inc · Expires 2018-09-05 · 8y expired

What this patent protects

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

USPTO Abstract

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Drugs covered by this patent

Patent Metadata

Patent number
EP3368012A1
Jurisdiction
EP
Classification
—
Expires
2018-09-05
Drug substance claim
No
Drug product claim
No
Assignee
Silvergate Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.